Milind Javle, MD - A New Dawn in the Therapeutic Management of Biliary Cancers: Integrating Precision Medicine With New and Emerging Targeted Strategies

Go online to PeerView.com/XXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a biliary cancer expert discusses the latest data on targeted treatments for biliary cancers and gives guidance on integrating precision medicine with new and emerging strategies. Upon completion of this activity, participants should be better able to: Describe the scientific rationale for therapeutic targeting in biliary cancers, including mechanisms involved with FGFR genomic aberrations, multikinase tumor pathways, HER2 expression, NTRK gene fusions, IDH1/2 mutations, and immune checkpoint pathways, Evaluate the latest clinical evidence of newly validated and emerging therapeutic strategies, such as FGFR, IDH, TRK, multikinase, HER2, and checkpoint inhibitors, in patients with advanced biliary cancers, Review ongoing clinical trials investigating novel approaches, such as chemotherapy platforms, targeted agents, and immunotherapy, that are recruiting patients with biliary cancers, Develop tailored treatment plans for patients with advanced biliary cancer, utilizing molecular testing and established and emerging targeted therapeutic strategies based on individual tumor characteristics.